Atezolizumab is a humanized IgG1-κ immune checkpoint inhibitor targets PD-L1 that commonly expressed on the surface of antigen presenting cells and tumor cells, and prevents its binding to the programmed cell death protein 1 (PD-1) receptor on T cells. Here, CD274 is linked to neoplasm.